Le Lézard
Classified in: Health, Business
Subjects: CON, VET

CMI/Compas, Through Its Partnership with HRS Consulting, is Part of the $1 Billion VHA Integrated Healthcare Transformation (IHT) Prime Contract Award


KING OF PRUSSIA, Pa., April 21, 2020 /PRNewswire-PRWeb/ -- CMI/Compas will support all media-related activities as part of a Veteran Health Administration (VHA) contract awarded to HRS Consulting Inc. by the Department of Veterans Affairs (VA) to provide best value healthcare and professional consulting services. CMI/Compas provides media strategy, planning, innovation and buying for the nation's top healthcare companies and is part of WPP.

Through the IHT vehicle, HRS will assist with completion of an organizational transformation that enhances VHA's capabilities to provide seamless, high-quality, integrated, coordinated healthcare, anytime and anywhere, by focusing on health system transformation and innovation, implementation and operations support, and healthcare business enabling services.

About the Contract: The VHA Office of Healthcare Transformation (OHT) and the Strategic Acquisition Center- Frederick (SAC-F) collaborated to put in place a ten-year multiple-award Indefinite-Delivery Indefinite-Quantity (IDIQ) contract. This contract supports the programmatic and transformation needs of VHA, including the Office of Healthcare Transformation and its customers, to best accomplish VHA's mission, strategic goals, healthcare priorities, and initiatives. The VHA IHT agreement has a collective ceiling of $1 Billion, and a period of performance of a 5-year base and one 5-year option.

The company delivers game-changing media performance and precision solutions to clients, fueled by talent, data, technology and amplification of creative. CMI/Compas also recently announced the creation of a growth & innovation practice, part of an overall strategy to continue strong growth and innovation.

CMI/Compas has brought many firsts to healthcare marketing as the leading healthcare-focused media buying and planning resource to the world's game changers in pharma and life sciences.

About CMI/Compas

Well-known as a media planning and buying organization for healthcare clients, sister agencies CMI Media, a WPP company, and Compas, Inc. together form the indispensable strategic marketing partner to the world's game-changers in health, offering guidance at every level of marketing. CMI/Compas focuses on core service offerings of Audience Strategy and Non-Personal Promotion Strategy, Planning, Buying, and Customer Insights and performance management/precision analytics. With continuous investment in the things that really matter, CMI and Compas have achieved unsurpassed tenure of healthcare marketing talent, clients and suppliers. CMI/Compas has eight offices across the US. https://cmimedia.com/

 

SOURCE CMI/Compas


These press releases may also interest you

at 07:08
Pulnovo Medical Limited, a globally recognized device pioneer in the treatment of Pulmonary Hypertension (PH) and Heart Failure (HF), is pleased to announce the successful initiation and first two patients enrollment for its global multicenter...

at 07:05
Bruker Corporation is pleased to announce the successful installation of a 1.2 GHz NMR spectrometer at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, accepted in the second quarter of 2024. This ultra-high field NMR...

at 07:05
KORU Medical Systems, Inc. ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today...

at 07:05
Satellos Bioscience Inc. ("Satellos" or the "Company") , a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced preliminary results from a single case...

at 07:00
ThirtyFiveBio Limited,...

at 07:00
DRI Healthcare Trust (the "Trust"), a global leader in providing financing to advance innovation in the life sciences industry, has acquired a second royalty interest in the worldwide net sales of Xenpozyme (olipudase alfa) from HLS...



News published on and distributed by: